Almoosa Health Company SJSC

Almoosa Health Company SJSC maintains a debt-to-equity ratio of 0.42, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.72, suggesting it can cover short-term obligations but with limited buffer. However, the company's free cash flow is negative at -284.63 million SAR, and capital expenditures are substantial at -531.03 million SAR, indicating significant reinvestment in operations. Profitability metrics show a return on equity of 12.29% and a return on assets of 7.14%, both above the industry median for healthcare facilities and services. The operating margin is 15.94% (calculated from operating income of 225.74 million SAR on revenue of 1.42 billion SAR), which is a strong indicator of operational efficiency. The gross margin of 31.67% (448.60 million SAR on 1.42 billion SAR revenue) also reflects effective cost control in production and distribution. The company's revenue is concentrated in a single business segment, pharmaceuticals, which accounts for 100% of total revenue. Geographically, the company is entirely focused on the domestic market, with no disclosed international operations. This concentration increases exposure to local economic and regulatory shifts. Looking ahead, the company is expected to grow revenue by 8.5% in the current fiscal year and 6.2% in the next, based on analyst estimates and historical performance. The mean price target of 183.47 SAR implies a 12.3% upside from the current share price. However, the negative free cash flow and high capital expenditures suggest that the company is reinvesting heavily in its operations, which may limit near-term shareholder returns. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. The company has not disclosed any recent dilutive events, and the number of shares outstanding has remained stable. Recent filings and transcripts indicate no material changes in the company's strategic direction or financial outlook. The company continues to focus on expanding its pharmaceutical product portfolio and improving healthcare delivery services. No significant regulatory or legal challenges have been disclosed in the latest filings.